23:55:21 Europe / Stockholm

Kalender

2024-08-20 Kvartalsrapport 2024-Q2
2024-04-11 Årsstämma 2024
2024-04-04 Bokslutskommuniké 2023
2023-12-06 Split ORPHA 1000:1
2023-11-02 Extra Bolagsstämma 2023
2023-09-12 Kvartalsrapport 2023-Q2
2023-05-22 Ordinarie utdelning ORPHA 0.00 DKK
2023-05-17 Årsstämma 2023
2023-04-25 Bokslutskommuniké 2022
2022-09-26 Kvartalsrapport 2022-Q2
2022-06-29 Årsstämma 2022
2022-06-28 Ordinarie utdelning ORPHA 0.00 DKK
2022-06-07 Bokslutskommuniké 2021
2022-02-15 Extra Bolagsstämma 2022
2021-08-31 Kvartalsrapport 2021-Q2
2021-03-26 Ordinarie utdelning ORPHA 0.00 DKK
2021-03-25 Årsstämma 2021
2021-03-02 Bokslutskommuniké 2020
2020-09-21 Extra Bolagsstämma 2020
2020-08-28 Kvartalsrapport 2020-Q2
2020-03-27 Ordinarie utdelning ORPHA 0.00 DKK
2020-03-26 Årsstämma 2020
2020-02-28 Bokslutskommuniké 2019
2020-01-25 Extra Bolagsstämma 2019
2019-08-28 Kvartalsrapport 2019-Q2
2019-03-28 Ordinarie utdelning ORPHA 0.00 DKK
2019-03-27 Årsstämma 2019
2019-03-01 Bokslutskommuniké 2018
2018-08-28 Kvartalsrapport 2018-Q2
2018-04-13 Ordinarie utdelning ORPHA 0.00 DKK
2018-04-12 Årsstämma 2018
2018-03-15 Bokslutskommuniké 2017

Beskrivning

LandDanmark
ListaSmall Cap Copenhagen
SektorHälsovård
IndustriBioteknik
Orphazyme är verksamt inom biokemi. Bolaget är specialiserat mot forskning och utveckling av ovanliga sjukdomar där det finns en brist i funktionen hos värmekokproteiner. Tekniken baseras på arimoklomol, som stimulerar produktionen av värmekokproteiner i celler som upplever en ökad grad av stress och toxicitet. Sjukdomar som ämnar behandlas med bolagets produkter innefattar Gauchers sjukdom och amyotrofisk lateral skleros (ALS). Bolaget har sitt huvudkontor i Köpenhamn.
Filter arrow-icon
År arrow-icon
Typ arrow-icon
Språk arrow-icon
2023-11-30 11:05:11 Finanskalender 2024 pdf download
2023-11-08 18:23:50 Business update October 2023 pdf download
2023-10-11 10:53:38 Notice of proposal to Consolidate Shares in Orphazyme A/S pdf download
2023-10-06 08:37:25 Share-based incentive program pdf download
2023-10-06 07:55:35 Preliminary court approval on US Security class action case pdf download
2023-09-20 20:52:20 New CEO appointed pdf download
2023-09-12 08:30:00 Interim Report First Half 2023 pdf download pdf download
2023-05-30 19:41:56 Change in management pdf download
2023-05-19 09:21:45 Major shareholder announcement pdf download
2023-05-17 18:51:34 Major shareholder announcement pdf download
2023-05-17 15:29:42 Resolutions passed at the Annual General Meeting pdf download pdf download
2023-05-17 12:44:58 Changes to the Board of Directors pdf download
2023-05-12 18:02:12 Major shareholder announcement pdf download
2023-05-09 10:45:00 Major shareholder announcement pdf download
2023-05-09 10:35:00 Major shareholder announcement pdf download
2023-04-25 22:27:00 Notice to convene Annual General Meeting pdf download pdf download pdf download
2022-09-25 22:09:16 Adjusted financial outlook for 2022 pdf download
2022-09-19 19:41:51 Updated financial calendar for 2022 pdf download
2022-06-29 16:27:05 Resolutions passed at the Annual General Meeting pdf download
2022-06-07 23:47:03 Notice to convene Annual General Meeting pdf download pdf download pdf download
2022-05-30 14:55:12 Restructuring proposal adopted by creditors pdf download
2022-05-23 08:52:08 Changes to the Board of Directors pdf download
2022-05-18 16:35:30 Restructuring Proposal pdf download pdf download
2022-05-16 14:50:25 Updated Financial Calendar for 2022 pdf download
2022-04-28 16:13:58 Updated Financial Calendar for 2022 pdf download
2022-04-07 12:08:00 Statutory restructuring plan adopted by creditors pdf download
2022-04-06 14:48:42 Updated Financial Calendar for 2022 pdf download
2022-04-04 19:44:00 Correction: Proposal for a statutory restructuring plan pdf download pdf download
2022-03-31 23:37:01 Voluntary delisting of ADSs has become effective pdf download
2022-03-31 18:00:00 Proposal for a statutory restructuring plan pdf download pdf download
2022-03-29 13:15:00 Updated Financial Calendar for 2022 pdf download
2022-03-21 22:44:00 Orphazyme A/S has filed for voluntary delisting of ADSs pdf download